MedTrace Logo

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

NCT00774046 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-02-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.

Conditions

Interventions

DRUG

Ara-C

Induction: 3000mg/m2 IV infusion for day 1 and day 5 Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)

DRUG

Mitoxantrone

Induction: 30mg/m2 after the end of HiDAC day 1 and day 5

DRUG

Etoposide

Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Lucy Godley, M.D. · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00774046 on ClinicalTrials.gov